Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 7;12:3647. doi: 10.1038/s41598-022-04840-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Comparative effects of fraction “K” and PXT on cell viability. Mean cell viability (± SD) measured by XTT assay for (A) PC12 cells incubated with concentrations of fraction “K” (0–2000 μg/mL) for 14 h or (B) PC12 cells pretreated with concentrations of fraction “K” (0–2000 μg/mL) for 2 h followed by incubation for 12 h with H₂O₂ (400 μM). Mean cell viability (± SD) measured by XTT assay for (C) PC12 cells incubated with concentrations of PXT (0–100 μM) for 14 h or (D) PC12 cells pretreated with concentrations PXT (0–100 μM) for 2 h followed by incubation for 12 h with H₂O₂ (400 μM). Two-way ANOVA: (A,B) Concentration, p < 0.0001; pretreatment, p < 0.0001; interaction, p < 0.0001. Sidak: all treatments, p < 0.0001; Dunnett’s test: (B) 500 μg/mL, p = 0.0006; 1000–2000 μg/mL, p < 0.0001. (C,D) Concentration, p < 0.0001; pretreatment, p < 0.0001; interaction, p < 0.0001. Sidak: all treatments, p < 0.0001; Dunnett’s test: (C) 25–100 μM, p < 0.0001; (D) all treatments, p < 0.0001. **, p = 0.0006; ***, p < 0.0001.